Shire’s Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation (CIC) in Adults

Shots:

• The approval is based on six trials assessing Motegrity vs PBO in 2,484 patients with Chronic Idiopathic Constipation (CIC) in adults
• P-III study results: normalization of BM frequency (19-38% vs 10-20%); no increase in the risk of MACE events
• Motegrity (prucalopride) is a qd serotonin-4 receptor agonist (5-HT4) with its expected launch in 2019 in the US

Click here to read full press release/ article | Ref: GlobeNewWire | Image: WSJ